1. Topical, Biological and Clinical Challenges in the Management of Patients with Acne Vulgaris
- Author
-
Tariq I. Mughal, Lynn McKinley-Grant, Sameer Al-Ali, Rajesh Ramadurai, Abla Al-Ismaily, Anwar Al-Hammadi, and Rishi Jain
- Subjects
0301 basic medicine ,benzoyl peroxide ,medicine.medical_specialty ,retinoids ,diagnosis ,Alternative medicine ,lcsh:Medicine ,Review ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,antibiotics ,medicine ,therapeutics ,acne vulgaris ,molecular biology ,Young adult ,Intensive care medicine ,Isotretinoin ,Acne ,business.industry ,Incidence (epidemiology) ,lcsh:R ,isotretinoin ,General Medicine ,medicine.disease ,Dermatology ,Optimal management ,Clinical trial ,030104 developmental biology ,business ,medicine.drug - Abstract
Acne vulgaris is one of the most common chronic inflammatory skin disorders among adolescents and young adults. It is associated with substantial morbidity and, rarely, with mortality. The exact worldwide incidence and prevalence are currently unknown. Current challenges involve improving understanding of the underlying pathophysiology of acne vulgaris and developing a practical treatment consensus. Expert panel discussions were held in 2013 and 2014 among a group of scientists and clinicians from the Omani and United Arab Emirate Dermatology Societies to ascertain the current optimal management of acne vulgaris, identify clinically relevant end-points and construct suitable methodology for future clinical trial designs. This article reviews the discussions of these sessions and recent literature on this topic.
- Published
- 2016